Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
5 "Dong Deuk Kwon"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Genitourinary cancer
Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus without Confirmatory Bone Scan
Chang Wook Jeong, Jang Hee Han, Dong Deuk Kwon, Jae Young Joung, Choung-Soo Kim, Hanjong Ahn, Jun Hyuk Hong, Tae-Hwan Kim, Byung Ha Chung, Seong Soo Jeon, Minyong Kang, Sung Kyu Hong, Tae Young Jung, Sung Woo Park, Seok Joong Yun, Ji Yeol Lee, Seung Hwan Lee, Seok Ho Kang, Cheol Kwak
Cancer Res Treat. 2024;56(2):634-641.   Published online December 5, 2023
DOI: https://doi.org/10.4143/crt.2023.848
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
In men with metastatic castration-resistant prostate cancer (mCRPC), new bone lesions are sometimes not properly categorized through a confirmatory bone scan, and clinical significance of the test itself remains unclear. This study aimed to demonstrate the performance rate of confirmatory bone scans in a real-world setting and their prognostic impact in enzalutamide-treated mCRPC.
Materials and Methods
Patients who received oral enzalutamide for mCRPC during 2014-2017 at 14 tertiary centers in Korea were included. Patients lacking imaging assessment data or insufficient drug exposure were excluded. The primary outcome was overall survival (OS). Secondary outcomes included performance rate of confirmatory bone scans in a real-world setting. Kaplan-Meier analysis and multivariate Cox regression analysis were performed.
Results
Overall, 520 patients with mCRPC were enrolled (240 [26.2%] chemotherapy-naïve and 280 [53.2%] after chemotherapy). Among 352 responders, 92 patients (26.1%) showed new bone lesions in their early bone scan. Confirmatory bone scan was performed in 41 patients (44.6%), and it was associated with prolonged OS in the entire population (median, 30.9 vs. 19.7 months; p < 0.001), as well as in the chemotherapy-naïve (median, 47.2 vs. 20.5 months; p=0.011) and post-chemotherapy sub-groups (median, 25.5 vs. 18.0 months; p=0.006). Multivariate Cox regression showed that confirmatory bone scan performance was an independent prognostic factor for OS (hazard ratio 0.35, 95% confidence interval, 0.18 to 0.69; p=0.002).
Conclusion
Confirmatory bone scan performance was associated with prolonged OS. Thus, the premature discontinuation of enzalutamide without confirmatory bone scans should be discouraged.

Citations

Citations to this article as recorded by  
  • ECM-mimicking hydrogel models of human adipose tissue identify deregulated lipid metabolism in the prostate cancer-adipocyte crosstalk under antiandrogen therapy
    Agathe Bessot, Joan Röhl, Maria Emmerich, Anton Klotz, Akhilandeshwari Ravichandran, Christoph Meinert, David Waugh, Jacqui McGovern, Jenni Gunter, Nathalie Bock
    Materials Today Bio.2025; 30: 101424.     CrossRef
  • 3,405 View
  • 134 Download
  • 1 Crossref
Close layer
Selection Criteria for Active Surveillance of Patients with Prostate Cancer in Korea: A Multicenter Analysis of Pathology after Radical Prostatectomy
Chang Wook Jeong, Sung Kyu Hong, Seok Soo Byun, Seong Soo Jeon, Seong Il Seo, Hyun Moo Lee, Hanjong Ahn, Dong Deuk Kwon, Hong Koo Ha, Tae Gyun Kwon, Jae Seung Chung, Cheol Kwak, Hyung Jin Kim
Cancer Res Treat. 2018;50(1):265-274.   Published online April 14, 2017
DOI: https://doi.org/10.4143/crt.2016.477
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Korean patients with prostate cancer (PC) typically present with a more aggressive disease than patients in Western populations. Consequently, it is unclear if the current criteria for active surveillance (AS) can safely be applied to Korean patients. Therefore, this study was conducted to define appropriate selection criteria for AS for patients with PC in Korea.
Materials and Methods
We conducted a multicenter retrospective study of 2,126 patients with low risk PC who actually underwent radical prostatectomy. The primary outcome was an unfavorable disease, which was defined by non-organ confined disease or an upgrading of the Gleason score to ≥ 7 (4+3). Predictive variables of an unfavorable outcome were identified by multivariate analysis using randomly selected training samples (n=1,623, 76.3%). We compared our selected criteria to various Western criteria for the primary outcome and validated our criteria using the remaining validation sample (n=503, 23.7%).
Results
A non-organ confined disease rate of 14.9% was identified, with an increase in Gleason score ≥ 7 (4+3) of 8.7% and a final unfavorable disease status of 20.8%. The following criteria were selected: Gleason score ≤ 6, clinical stage T1-T2a, prostate-specific antigen (PSA) ≤ 10 ng/mL, PSA density < 0.15 ng/mL/mL, number of positive cores ≤ 2, and maximum cancer involvement in any one core ≤ 20%. These criteria provided the lowest unfavorable disease rate (11.7%) when compared to Western criteria (13.3%-20.7%), and their validity was confirmed using the validation sample (5.9%).
Conclusion
We developed AS criteria which are appropriate for Korean patients with PC. Prospective studies using these criteria are now warranted.

Citations

Citations to this article as recorded by  
  • Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS‐JAPAN)
    Takuma Kato, Ryuji Matsumoto, Akira Yokomizo, Yoichiro Tohi, Hiroshi Fukuhara, Yoichi Fujii, Keiichiro Mori, Takuma Sato, Junichi Inokuchi, Katsuyoshi Hashine, Shinichi Sakamoto, Hidefumi Kinoshita, Koji Inoue, Toshiki Tanikawa, Takanobu Utsumi, Takayuki
    BJU International.2024; 134(4): 652.     CrossRef
  • Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry
    Chris Bangma, Paul Doan, Lin Zhu, Sebastiaan Remmers, Daan Nieboer, Jozien Helleman, Monique J. Roobol, Mikio Sugimoto, Byung Ha Chung, Lui Shiong Lee, Mark Frydenberg, Laurence Klotz, Michael Peacock, Antoinette Perry, Anders Bjartell, Antti Rannikko, Mi
    European Urology Oncology.2024;[Epub]     CrossRef
  • Establishment of Prospective Registry of Active Surveillance for Prostate Cancer: The Korean Urological Oncology Society Database
    Gyoohwan Jung, Jung Kwon Kim, Seong Soo Jeon, Jae Hoon Chung, Cheol Kwak, Chang Wook Jeong, Hanjong Ahn, Jae Young Joung, Tae Gyun Kwon, Sung Woo Park, Seok-Soo Byun
    The World Journal of Men's Health.2023; 41(1): 110.     CrossRef
  • The Role of Magnetic Resonance Imaging (MRI) and MRI-Targeted Biopsy for Active Surveillance
    Chang Wook Jeong
    Journal of Urologic Oncology.2023; 21(2): 97.     CrossRef
  • Incidence and mortality projections for major cancers among Korean men until 2034, with a focus on prostate cancer
    Sahyun Pak, Kyu-Won Jung, Eun-Hye Park, Young Hwii Ko, Young-Joo Won, Jae Young Joung
    Investigative and Clinical Urology.2022; 63(2): 175.     CrossRef
  • Role of single nucleotide polymorphisms of the HSD3B1 gene (rs6203 and rs33937873) in the prediction of prostate cancer risk
    Yasmine Amrousy, Hesham Haffez, Doaa Abdou, Hanaa Atya
    Molecular Medicine Reports.2022;[Epub]     CrossRef
  • A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up
    Sang Hun Song, Jung Kwon Kim, Hakmin Lee, Sangchul Lee, Sung Kyu Hong, Seok-Soo Byun
    Investigative and Clinical Urology.2021; 62(1): 32.     CrossRef
  • The clinical impact of strict criteria for active surveillance of prostate cancer in Korean population: Results from a prospective cohort
    Jungyo Suh, Hyeong Dong Yuk, Minyong Kang, Bum Sik Tae, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak, Chang Wook Jeong
    Investigative and Clinical Urology.2021; 62(4): 430.     CrossRef
  • Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database
    Kerri Beckmann, Aida Santaolalla, Jozien Helleman, Peter Carroll, Byung Ha Chung, Lui Shiong Lee, Antoinette Perry, Jose Rubio-Briones, Mikio Sugimoto, Bruce Trock, Riccardo Valdagni, Prokar Dasgupta, Mieke Van Hemelrijck, Oussama Elhage, Bruce Trock, Beh
    European Urology Open Science.2021; 34: 47.     CrossRef
  • Patients with Biopsy Gleason Score 3 + 4 Are Not Appropriate Candidates for Active Surveillance
    Juhyun Park, Sangjun Yoo, Min Chul Cho, Chang Wook Jeong, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Hyeon Jeong
    Urologia Internationalis.2020; 104(3-4): 199.     CrossRef
  • Current status and progress of focal therapy in Asia
    Takumi Shiraishi, Osamu Ukimura
    Current Opinion in Urology.2018; 28(6): 529.     CrossRef
  • The MMP2 rs243865 polymorphism increases the risk of prostate cancer: A meta-analysis
    Kun Liu, Shuo Gu, Xuzhong Liu, Qing Sun, Yunyan Wang, Junsong Meng, Zongyuan Xu
    Oncotarget.2017; 8(42): 72933.     CrossRef
  • 9,106 View
  • 249 Download
  • 9 Web of Science
  • 12 Crossref
Close layer
Poor Preoperative Glycemic Control Is Associated with Dismal Prognosis after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Korean Multicenter Study
Sung Gu Kang, Eu Chang Hwang, Seung Il Jung, Ho Song Yu, Ho Seok Chung, Taek Won Kang, Dong Deuk Kwon, Jun Eul Hwang, Jun Seok Kim, Joon Hwa Noh, Jae Hyung You, Myung Ki Kim, Tae Hoon Oh, Ill Young Seo, Seung Baik, Chul-Sung Kim, Seok Ho Kang, Jun Cheon
Cancer Res Treat. 2016;48(4):1293-1301.   Published online March 23, 2016
DOI: https://doi.org/10.4143/crt.2016.021
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to evaluate the effect of diabetes mellitus (DM) and preoperative glycemic control on prognosis in Korean patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy (RNU). Materials and Methods A total of 566 patients who underwent RNU at six institutions between 2004 and 2014 were reviewed retrospectively. Kaplan-Meier and Cox regression analyses were performed to assess the association between DM, preoperative glycemic control, and recurrence-free, cancer-specific, and overall survival.
Results
The median follow-up period was 33.8 months (interquartile range, 41.4 months). A total of 135 patients (23.8%) had DM and 67 patients (11.8%) had poor preoperative glycemic control. Patients with poor preoperative glycemic control had significantly shorter median recurrence-free, cancer-specific, and overall survival than patients with good preoperative glycemic control and non-diabetics (all, p=0.001). In multivariable Cox regression analysis, DM with poor preoperative glycemic control showed association with worse recurrence-free survival (hazard ratio [HR], 2.26; 95% confidence interval [CI], 1.31 to 3.90; p=0.003), cancer-specific survival (HR, 2.96; 95% CI, 1.80 to 4.87; p=0.001), and overall survival (HR, 2.13; 95% CI, 1.40 to 3.22; p=0.001). Conclusion Diabetic UTUC patients with poor preoperative glycemic control had significantly worse oncologic outcomes than diabetic UTUC patients with good preoperative glycemic control and non-diabetics. Further investigation is needed to elucidate the exact mechanism underlying the impact of glycemic control on UTUC treatment outcome.

Citations

Citations to this article as recorded by  
  • Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians
    Laura Ashley, Saifuddin Kassim, Ian Kellar, Lisa Kidd, Frances Mair, Mike Matthews, Mollie Price, Daniel Swinson, Johanna Taylor, Galina Velikova, Jonathan Wadsley
    BMJ Open.2022; 12(2): e060402.     CrossRef
  • Annular-shaped stenosis in the ureter: Caution should be taken
    Jie Ming, Yue Wang, Ziliang Su, Chunyang Wang
    Urologic Oncology: Seminars and Original Investigations.2022; 40(6): 274.e7.     CrossRef
  • Glycosylated haemoglobin and prognosis in 10,536 people with cancer and pre-existing diabetes: a meta-analysis with dose-response analysis
    Suping Ling, Michael Sweeting, Francesco Zaccardi, David Adlam, Umesh T. Kadam
    BMC Cancer.2022;[Epub]     CrossRef
  • Malnutrition management of hospitalized patients with diabetes/hyperglycemia and cancer cachexia
    Rosa Burgos Peláez, José Pablo Suárez Llanos, Jose Manuel García Almeida, Pilar Matía Martín, Samara Palma Milla, Alejandro Sanz Paris, Ana Zugasti Murillo, Ana Artero-Fullana, Alfonso Calañas Continente, M.ª Jesús Chinchetru, Katherine García Malpartida,
    Nutrición Hospitalaria.2022;[Epub]     CrossRef
  • The Impact of Diabetes on the Prognosis of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
    Xiaoshuai Gao, Liang Zhou, Jianzhong Ai, Wei Wang, Xingpeng Di, Liao Peng, Banghua Liao, Xi Jin, Hong Li, Kunjie Wang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • The Prognostic Value of Lymphovascular Invasion in Patients With Upper Tract Urinary Carcinoma After Surgery: An Updated Systematic Review and Meta-Analysis
    Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Jun Yuan, Yejun Feng
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • The impact of preoperative glycated hemoglobin levels on outcomes in oral squamous cell carcinoma
    Ze Yun Tay, Huang‐Kai Kao, Kuang‐Hsu Lien, Shao‐Yu Hung, Yenlin Huang, Ngan‐Ming Tsang, Kai‐Ping Chang
    Oral Diseases.2020; 26(7): 1449.     CrossRef
  • 10,798 View
  • 120 Download
  • 8 Web of Science
  • 7 Crossref
Close layer
The Clinical Usefulness of Membranous E-cadherin in Transitional Cell Carcinoma of the Bladder
Bong Ryoul Oh, Gil Joo Nah, Seong Jin Kim, Jae Hong Sim, Dong Deuk Kwon, Kwang Sung Park, Soo Bang Ryu, Yang Il Park
J Korean Cancer Assoc. 1998;30(6):1219-1226.
AbstractAbstract PDF
PURPOSE
E-cadherin, a cell adhesive molecule that plays a diverse role in cell-cell and cell-matrix interaction, is essential for maintaining epithelial intercellular adhesion and acts particularly as a suppressor of invasive ability of cancer. To detennine the potential pro- gnostic values of membranous E-cadherin, we evaluated the correlation between the clin- ical outcome and its expression in patients with transitional cell carcinoma of the bladder.
MATERIALS AND METHODS
Membranous E-cadherin immunoreactivity was evaluated in 75 cases of transitional bladder cancer and 15 controls (5 cases of cystitis and 10 normal controls). The expression of membranous E-cadherin were compared with histological grade, T category of TNM stage, and survival.
RESULTS
Abnonnal immunohistochemical expression of membranous E-cadherin was observed in 53 (70.7%) patients with bladder cancer and undetected in controis. Abnormal immunohistochemical expression of membranous E-cadherin was significantly correlated with grade (p<0.01) and T category of TNM stage (p<0.01) of transitional cell carcinoma of the bladder. Progression to invasive cancer occurred in 6 patients with 45 superficial bladder cancer and 5 of them showed abnormal expression of E-cadherin, which had statistical significance (p<0.05) but not with recurrence. There was statistically significant correlation between the abnormal expression of E-cadherin and poor prognosis (p < 0.01).
CONCLUSIONS
We conclude that abnormal expression of membranous E-cadherin is a useful prognostic marker in patients with transitional bladder cancer.
  • 2,552 View
  • 14 Download
Close layer
Urinary Nuclear Matrix Protein ( NMP 22 ) in the Detection of Transitional Cell Carcinoma of the Bladder
Soo Bang Ryu, Bong Ryoul Oh, Soon Pal Suh, Dong Deuk Kwon, Je Woong Ryu, Yang Il Park
J Korean Cancer Assoc. 1998;30(2):378-383.
AbstractAbstract PDF
PURPOSE
The detection of bladder cancers by noninvasive techniques remains an unsolved problem. We evaluate the availability of an immunoassay for urinary nuclear matrix protein, NMP 22, as an indicator for transitional cell carcinoma of the bladder.
MATERIALS AND METHODS
Three groups of subjects participated in this trial of NMP 22: 22 patients with transitional cell carcinoma (group 1), 12 patients with urinary tract infection (group 2) and 31 healthy volunteers (group 3). NMP 22 was determined by ELISA using a commercial test kit (NMP 22 Test Kit, Matritech Inc., USA), We compared urinary NMP 22 levels to the grade, stage, cytology and DNA flowcytometry of transitional cell carcinoma of bladder.
RESULTS
NMP 22 values in these 3 groups were significantly different (group 1, median 24.81 U/mL; group 2, median 8.41 U/mL; and group 3, median 5.12 U/mL; Mann-Whitney U test for differences between 3 medians, p < 0.05). The patients with transitional cell carcinoma had significantly greater urinary NMP 22 levels than those with no evidence of tumor (Mann-Whitney U test for differences between 2 medians, p<0.01). There was no zelationship between the urinary NMP 22 levels and tumor grade, stage, cytology or DNA flowcytometry.
CONCLUSIONS
It is possible that urinary NMP 22 could improve the detection of bladder transitional cell carcinoma.
  • 2,522 View
  • 19 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP